Chinese researchers discover new apoptosis regulator Bcl-2 inhibitors
July 10, 2023
Biopolar Hongye (Nantong) Pharmaceutical Co. Ltd. and Hangzhou Hertz Pharmaceutical Co. Ltd. have described apoptosis regulator Bcl-2 wild-type, Bcl-2 (D103Y mutant) and/or Bcl-2 (G101V mutant) inhibitors reported to be useful for the treatment of cancer, infections, immunological and inflammatory disorders.